Given Verastem's (VSTM) depressing price movement since reaching $10 in 2018 and AVEO's volatile start to 2019, neither company has brought forth any interesting data for presentation at ASCO 2019. … [Read more...] about Lackluster ASCO for Verastem and AVEO
duvelisib
Verastem’s Earnings: Is It a Buy Now?
Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?
Can Verastem Shake the DownTrend?
Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
(Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Lymphoma Patients Want and Need A Better Quality Of Life As a Lymphoma survivor, I can say unequivocally, that TO MUCH TIME is spent in the chemo wing, away from our families. Therefore, as … [Read more...] about (Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
You must be logged in to post a comment.